AstraZeneca and Sanofi Beyfortus to dominate RSV market in China: GlobalData
In 2017, Sanofi entered into a collaboration agreement with MedImmune (AstraZeneca) to jointly develop and commercialise Beyfortus
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
respiratory syncytial virus
Biden administration to urge Americans get COVID-19 boosters
The official said that while the Centers for Disease Control and Prevention are reporting an increase in infections and hospital…
Pfizer and GSK to battle for share of new RSV vaccine market: GlobalData
Pfizer's RSV vaccine, Abrysvo, approved by the FDA just weeks after Arexvy, is likely to show GSK significant competition
New RSV therapies may accelerate the emergence of drug-resistant strains: GlobalData
Antibody-resistant mutations have already been documented in RSV after the administration of AstraZeneca/Sanofi's new RSV mAb,…
Sanofi and AstraZeneca win EU approval for prevention of infant RSV
The long-acting therapy, also known as nirsevimab, was given the European Union (EU) marketing authorisation for the prevention of…
Nirsevimab gets Promising Innovative Medicine Designation from MHRA
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus…